MedTrace Logo

Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris

NCT00662727 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2013-02-20

No results posted yet for this study

Summary

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

Conditions

  • Refractory Angina Pectoris

Interventions

DEVICE

Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)

Energy Density - 0.09 mJ/mm2

DEVICE

Placebo

Placebo

Sponsors & Collaborators

  • Hadassah Medical Organization

    collaborator OTHER

  • Medispec

    lead INDUSTRY

Principal Investigators

  • David Leibowitz, MD · Hadassah Medical Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2012-06-30
Completion
2012-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00662727 on ClinicalTrials.gov